Latest Insider Transactions at Ani Pharmaceuticals Inc (ANIP)
This section provides a real-time view of insider transactions for Ani Pharmaceuticals Inc (ANIP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANI PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANI PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,210
-3.32%
|
$397,440
$64.26 P/Share
|
|
Mar 23
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,455
-3.59%
|
$1,117,120
$64.26 P/Share
|
|
Mar 19
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,866
-2.81%
|
$121,290
$65.0 P/Share
|
|
Mar 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.49%
|
$25,200
$63.33 P/Share
|
|
Mar 07
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
3,314
-3.52%
|
$198,840
$60.62 P/Share
|
|
Mar 07
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,060
-3.39%
|
$1,023,600
$60.62 P/Share
|
|
Mar 07
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
2,874
-2.52%
|
$172,440
$60.62 P/Share
|
|
Mar 07
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,150
-2.68%
|
$309,000
$60.62 P/Share
|
|
Mar 07
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.48%
|
$60,000
$60.86 P/Share
|
|
Mar 05
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
5,384
-2.71%
|
$323,040
$60.01 P/Share
|
|
Mar 05
2025
|
Ori Gutwerg SVP, GENERICS |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.3%
|
$9,300
$31.49 P/Share
|
|
Feb 28
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
627
-1.36%
|
$38,247
$61.89 P/Share
|
|
Feb 28
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,216
-2.37%
|
$745,176
$61.89 P/Share
|
|
Feb 28
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,275
-1.1%
|
$77,775
$61.89 P/Share
|
|
Feb 28
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-1.6%
|
$67,039
$61.89 P/Share
|
|
Feb 28
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,570
-1.56%
|
$95,770
$61.89 P/Share
|
|
Feb 28
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,861
-0.96%
|
$113,521
$61.89 P/Share
|
|
Feb 28
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-1.34%
|
$67,039
$61.89 P/Share
|
|
Feb 21
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-1.44%
|
$60,000
$60.2 P/Share
|
|
Feb 15
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-1.15%
|
$67,686
$58.92 P/Share
|
|
Feb 15
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-1.02%
|
$68,672
$58.92 P/Share
|
|
Feb 14
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,426
-1.38%
|
$82,708
$58.92 P/Share
|
|
Feb 14
2025
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,799
-1.49%
|
$452,342
$58.92 P/Share
|
|
Feb 14
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,473
-1.25%
|
$85,434
$58.92 P/Share
|
|
Feb 14
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.25%
|
$33,756
$58.92 P/Share
|
|
Feb 14
2025
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-0.88%
|
$100,340
$58.92 P/Share
|
|
Feb 14
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,434
-1.72%
|
$83,172
$58.92 P/Share
|
|
Feb 14
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,196
-1.69%
|
$69,368
$58.92 P/Share
|
|
Feb 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.48%
|
$23,600
$59.54 P/Share
|
|
Feb 12
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+12.06%
|
-
|
|
Feb 12
2025
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
26,112
+11.81%
|
-
|
|
Feb 12
2025
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
152,331
+13.48%
|
-
|
|
Feb 12
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+15.95%
|
-
|
|
Feb 12
2025
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
BUY
Grant, award, or other acquisition
|
Direct |
13,056
+12.98%
|
-
|
|
Feb 12
2025
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
41,346
+9.97%
|
-
|
|
Feb 12
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
28,290
+15.42%
|
-
|
|
Feb 12
2025
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,761
+14.16%
|
-
|
|
Feb 12
2025
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
23,936
+14.91%
|
-
|
|
Jan 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.71%
|
$21,200
$53.92 P/Share
|
|
Dec 17
2024
|
Stephen P. Carey SVP & CFO |
SELL
Open market or private sale
|
Direct |
7,500
-4.63%
|
$412,500
$55.79 P/Share
|
|
Dec 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,000
$56.24 P/Share
|
|
Dec 11
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-2.0%
|
$60,000
$60.0 P/Share
|
|
Nov 26
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
33,481
-4.18%
|
$1,941,898
$58.13 P/Share
|
|
Nov 26
2024
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.91%
|
$870,000
$29.0 P/Share
|
|
Nov 15
2024
|
Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-2.55%
|
$48,552
$56.58 P/Share
|
|
Nov 15
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
6,500
-7.81%
|
$370,500
$57.7 P/Share
|
|
Nov 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$15,250
$61.36 P/Share
|
|
Oct 14
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,250
$57.19 P/Share
|
|
Sep 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.44%
|
$14,000
$56.82 P/Share
|
|
Sep 12
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,486
-2.88%
|
$83,216
$56.15 P/Share
|